![]() |
|
|
Vol. 280, Issue 1, 268-276, 1997
Department of Pharmacology (N.-Y.H., R.M.K.) and
Internal Medicine
(C.L.), Quillen College of Medicine, East Tennessee State University,
Johnson City, Tennessee, and
Lilly Research Laboratories, Eli Lilly and
Company (K.W.P., R.W.F.), Lilly Corporate Center, Indianapolis, Indiana
To investigate the influence of dopamine (DA) nerves on haloperidol
(HAL)-induced oral dyskinesias, rats were first injected at 3 days
after birth with 6-hydroxydopamine HBr (200 µg i.c.v., salt form;
6-OHDA) or vehicle, after desipramine HCl (20 mg/kg i.p., 1 hr)
pretreatment. Two months later HAL (1.5 mg/kg/day, 2 days a week for 4 weeks, then daily for 10 months) was added to the drinking water of
half the rats. Numbers of vacuous chewing movements, recorded in 1-min
increments every 10 min for 1 hr, increased from <5 to about 17 oral
movements per session in intact rats, 14 weeks after instituting HAL
(P < .01 vs. intact rats drinking tap water). In
HAL-treated 6-OHDA-lesioned rats, oral activity increased to >30 oral
movements per session (P < .01 vs. HAL-treated
intact rats). These levels of oral activity persisted in intact and
6-OHDA-lesioned rats as long as HAL was administered. After 11 months
of HAL treatment, but 8 or 9 days after HAL withdrawal, DA was found to
be reduced 97%, whereas serotonin was increased 29% in the striatum
of 6-OHDA-lesioned rats. In HAL-treated intact and lesioned rats the
Bmax for DA D2 binding sites was
elevated about 70%. With reverse transcription polymerase chain
reaction, the mRNA level for DA D2L but not D2S
receptors was also found to be elevated about 70%. In a fraction of
6-OHDA-lesioned rats that were observed for 8 months after HAL
withdrawal, oral activity persisted without decrement and was not
accompanied by a change in the Bmax or mRNA
level for DA D2 receptors. These findings demonstrate that
in rats largely DA-denervated as neonates, long-term HAL treatment
produces an unusually high number of oral movements that persists for 8 months after HAL withdrawal and is not accompanied by an increase in DA
D2 receptor expression.